Sector News

Italy's Dompe Farmaceutici mulls listing as part of shift to biotech

October 26, 2018
Life sciences

Family-owned Italian biopharmaceutical group Dompe Farmaceutici is considering a listing of its shares as it looks to focus more on its biotech business and treating specific diseases.

“In 3-4 years we could consider a flotation perhaps in the U.S.,” Chief Executive Sergio Dompe said.

Dompe, son of company founder Franco Dompe, said other options also existed, including a reverse merger – or buying a listed business – in the United States, one of the company’s key markets.

The CEO said private equity firms, as well as some European and U.S. industrial players, had made contact with a view to buying the company.

“I told them not to bother since I will never sell,” he said.

Italy has a thriving pharmaceutical sector. But it is fragmented and analysts believe it could benefit from consolidation.

In June, family-controlled Recordati was snapped up by a consortium of investment funds controlled by CVC Capital Partners in a deal worth about 3 billion euros ($3.4 billion).

Dompe Farmaceutici, headquartered in Milan, employs around 800 people and had sales last year of 250 million euros.

Six patients dead after New Jersey virus outbreak
Earlier this year the U.S. Food and Drug Administration approved its new product based on cenegermin – the first drug for the treatment of rare eye disease neurotrophic keratitis.

Dompe, who hopes to be able to market the new treatment in China, said the new cenegermin-based drug was a game changer that could help boost margins over time and support investments in research and development.

“I’m looking to make this company a pharmaceutical biotech business with a focus on particular diseases,” Dompe said. ($1 = 0.8786 euros)

By Stephen Jewkes

Source: Reuters

comments closed

Related News

April 20, 2024

CureVac and MD Anderson Cancer Center partner to develop new cancer vaccines

Life sciences

CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.

April 20, 2024

FUJIFILM plans $1.2 billion investment in major US manufacturing facility

Life sciences

FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.

April 20, 2024

Sanofi cuts staff in Belgium as early-stage research dwindles

Life sciences

Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.

How can we help you?

We're easy to reach